Trump's New Drug Platform Could Shake Up Pharma Industry

Mark Cuban comments on President Trump's new drug platform, TrumpRx.gov, which aims to sell discounted prescription drugs directly to consumers. Cuban sees potential if it can challenge existing pharmacy benefit managers (PBMs), though current market reactions suggest skepticism. The platform partners with Pfizer and could influence drug pricing, but experts doubt it will significantly lower costs for most Americans due to systemic issues with PBMs and insurance-based purchasing.